Corporate Council

Corporate Council Members

  • The image shows the logo of Amgen, featuring the word "AMGEN" in bold blue letters with a modern, sans-serif font against a white background.
  • The Apogee Therapeutics logo features a stylized blue geometric “A” symbol to the left, with the words “APOGEE THERAPEUTICS” in blue, modern font to the right on a white background.
  • Logo of Aquestive Therapeutics featuring a stylized circular design in shades of blue followed by the name "Aquestive" in bold black lettering on a white background.
  • Logo of ARS Pharma featuring a stylized blue geometric shape with a green triangular element on the left and the words "ARS Pharma" in blue and green text on the right.
  • Logo of AstraZeneca featuring a stylized yellow emblem above the name "AstraZeneca" in purple text.
  • Logo for Blueprint Medicines, featuring a stylized DNA strand next to the company name, with the text “a Sanofi company” underneath.
  • The image shows the Chiesi logo, featuring a stylized hexagonal shape with an arrow and dot in pink, next to the text "Chiesi" in bold black letters.
  • Logo featuring two concentric circles above a curved line, resembling sound waves, with the text "dbv technologies" below in lowercase letters. The design uses shades of blue and gray on a white background.
  • The image shows the Genentech logo, featuring the word "Genentech" in blue, stylized, bold font on a white background.
  • The image shows the GSK logo with the letters "GSK" in a bold, modern orange font on a white background.
  • Logo of Incyte featuring the name in blue text with two overlapping circles, one in light blue and the other in green, partially encircling the text.
  • The image shows the Johnson & Johnson logo, with the brand name written in bold, red, cursive-style lettering on a white background.
  • The image shows the logo for Kaléo, a pharmaceutical company. The word "kaléo" is written in lowercase dark blue letters, with an accent over the letter "e" and a registered trademark symbol next to it.
  • Orange and white logo displaying the text "KYOWA KIRIN" with a stylized "K" inside an orange circle on the left.
  • The image shows the Kymera logo with the letter "K" in orange and the remaining letters "YMERA" in dark blue on a white background.
  • Red cursive "Lilly" logo with the text "A Medicine Company" in red capital letters below it. The background is white.
  • Logo of Novartis featuring a stylized orange and yellow flame design with a vertical blue element at the center above the brand name "Novartis" in blue capital letters.
  • Reacta Healthcare logo with a blue abstract heart or overlapping lines design on the left and the words "Reacta healthcare" in blue text on the right.
  • Sanofi logo featuring a large stylized black "S" with a purple dot, followed by the word "sanofi" in lowercase black letters, accented with purple dots on the "s" and "i," on a white background.
  • Logos of two companies: "sanofi" in black with purple dots on the "s" and "i," and "REGENERON" in blue, below the sanofi logo.
  • Viatris logo featuring a stylized globe with purple and yellow swoosh-like arcs next to the company name written in bold, dark blue letters.

Allergy & Asthma Network’s Corporate Council is a critical collaboration between the organization and high-level industry and partner leaders. The Corporate Council is focused on advancing Allergy & Asthma Network’s mission and values as well as mutual, appropriate goals of improving health outcomes. Grounded in transparency and innovation, membership in Corporate Council demonstrates partnership and a shared commitment to improve the lives and health of people with allergies, asthma and related conditions.

Members of Corporate Council convene annually to:

  • Receive updates on key priorities, goals and impact across the organization’s mission pillars.
  • Explore strategies to educate, advocate and advance research and health equity.
  • Discuss key issues among Council members and Network leadership that can be addressed collectively.

In addition to the annual meeting, Corporate Council members communicate with Allergy & Asthma Network’s leadership team throughout the year to:

  • Discuss key issues and their implications, such as access issues and guidelines-based care.
  • Create a better value proposition for both partners.
  • Discuss partnership opportunities that arise during the year
  • Gain insights from the patient perspective.
  • Discuss key advocacy issues and trends.

Corporate Council members are acknowledged every year at the annual Corporate Council meeting, and while exhibiting at professional meetings

For more information on how to become a member of our Corporate Council, please contact Lynda Mitchell, CEO.